ID: ALA4875400

Max Phase: Preclinical

Molecular Formula: C16H19N3O3

Molecular Weight: 301.35

Molecule Type: Unknown

Representations

Canonical SMILES:  CC1(CCC(=O)N2CCc3ccccc3C2)NC(=O)NC1=O

Standard InChI:  InChI=1S/C16H19N3O3/c1-16(14(21)17-15(22)18-16)8-6-13(20)19-9-7-11-4-2-3-5-12(11)10-19/h2-5H,6-10H2,1H3,(H2,17,18,21,22)

Standard InChI Key:  UIUVEDUDHUPZFS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 301.35

Molecular Weight (Monoisotopic): 301.1426

AlogP: 0.95

#Rotatable Bonds: 3

Polar Surface Area: 78.51

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.90

CX Basic pKa:

CX LogP: 0.60

CX LogD: 0.59

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.82

Np Likeness Score: -0.91

References

1. Brebion F, Gosmini R, Deprez P, Varin M, Peixoto C, Alvey L, Jary H, Bienvenu N, Triballeau N, Blanque R, Cottereaux C, Christophe T, Vandervoort N, Mollat P, Touitou R, Leonard P, De Ceuninck F, Botez I, Monjardet A, van der Aar E, Amantini D..  (2021)  Discovery of GLPG1972/S201086, a Potent, Selective, and Orally Bioavailable ADAMTS-5 Inhibitor for the Treatment of Osteoarthritis.,  64  (6.0): [PMID:33719441] [10.1021/acs.jmedchem.0c02008]

Source

Source(1):

• Scientific Literature